A Phase 3 Multicenter, Randomized, Controlled, and Open-Label Study of IN10018 in Combination With D-1553 Versus Standard Therapy for the Treatment of First Line Locally-advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell lung cancer (NSCLC).

Start Date01 Sep 2025

Sponsor / Collaborator

Inxmed (Shanghai) Co., Ltd

NCT06435455

/ Not yet recruitingPhase 1/2

A Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GH21 Capsule Combined With D-1553 Tablets in Patients With Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation

This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation.

Start Date01 Jul 2024

Sponsor / Collaborator

Qinhao Pharmaceutical (Suzhou) Co., Ltd.

[+1]

NCT06300177

/ RecruitingPhase 3

A Randomized, Controlled, Double-blind, Double-simulated, Multicenter Phase III Clinical Study Evaluating D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure.

The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat sarcoma viral oncogene (KRAS) G12C mutation positive locally advanced or metastatic non small cell lung cancer (NSCLC), progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) based on RECIST 1.1 was used as the primary endpoint.

Start Date28 Mar 2024

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with Garsorasib

100 Translational Medicine associated with Garsorasib

100 Patents (Medical) associated with Garsorasib

Literatures (Medical) associated with Garsorasib

01 Sep 2025·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

An overview of PROTACs targeting KRAS and SOS1 as antitumor agents

Review

Author: Rao, Hongxin ; Zhou, Chuan ; Xu, Tianfeng ; Han, Zhiqiu ; Wu, Qianping

KRAS is the most frequently mutated oncogene and its mutational activation drives approximately 25 % of human cancers. Son of Sevenless 1 (SOS1) plays a pivotal role in the KRAS signaling pathway through catalyzing the conversion of inactive GDP-bound KRAS to active GTP-bound KRAS, and is thus considered as a promising target for pan-KRAS inhibition. Currently, four KRAS^G12C-specific inhibitors, namely sotorasib, adagrasib, fulzerasib and garsorasib, have garnered regulatory approval. However, acquired resistance to KRAS^G12C inhibition rapidly emerges. In addition, the other prevalent KRAS mutations, including G12D and G12V, are still lacking effective therapeutic drugs. PROTAC-mediated KRAS and SOS1 degradation has been emerged as a promising strategy to overcome these issues, and achieved rapid progress in the recent years. This article provides an overview of the chemical structures, design strategies, structure-activity relationship (SAR) studies as well as in vitro and in vivo activities of the PROTACs degrading KRAS and SOS1, and sheds light on future challenges and opportunities to accelerate the development of new chemotherapies for KRAS-driven cancers.

01 Jul 2025·Translational Lung Cancer Research

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer

Review

Author: Dai, Xian-Zi ; Hao, Yue ; Yuan, Jiang-Xia ; Hong, Jiao-Jiao ; Chen, Cheng-Yu ; Huo, Zheng-Xing ; Zhu, Jia ; Wang, Qian

Background and Objective:

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are one of the most common oncogenic driver mutations in non-small cell lung cancer (NSCLC), with the KRAS G12C mutation being the most common prevalent subvariant. The review aims to explore optimal diagnostic and therapeutic strategies for KRAS G12C mutant NSCLC, and to provide guidance for the development of precise treatment approaches for affected.

Methods:

A comprehensive search was conducted in PubMed, Embase, Web of Science, MEDLINE, the Cochrane Library, and major international conferences proceedings for all English-language publications available up to December 31, 2024. Relevant studies were systematically reviewed, analyzed, and synthesized to inform this review.

Key Content and Findings:

In this review, we explore the KRAS G12C mutation and its associated signaling pathways, detection techniques, recent advancements in drug development and mechanisms of therapeutic resistance. The KRAS G12C mutation was once considered "undruggable" until the breakthrough approval of two targeted inhibitors: AMG510 (sotorasib) and MRTX849 (adagrasib). In China, IBI351 and D-1553 have also been approved for the treatment of adult patients with advanced NSCLC harboring the KRAS G12C mutation. Although currently approved only as second-line therapies for metastatic disease, these inhibitors-along with ongoing development of additional KRAS-targeted agents-are significantly advancing our understanding of KRAS-driven tumor biology. Notably, recent findings indicate that combining dual immune checkpoint inhibitors (ICIs; durvalumab and tremelimumab) with chemotherapy (CT) in patients with advanced NSCLC, including those with KRAS mutations, can result in durable survival benefits. This approach is emerging as a promising first-line treatment strategy.

Conclusions:

The landscape of KRAS-mutant NSCLC has undergone substantial progress, marked by the successive approval of multiple KRAS G12C inhibitors and the development of novel targeted therapies. Moreover, the POSEIDON trial has highlighted the potential of dual ICI therapy combined with CT to achieve sustained clinical benefits. Despite these advances, the heterogeneity of tumor responses underscores the need for further investigation into intrinsic resistance mechanisms and the strategic optimization of combination therapies to enhance treatment outcomes.

17 Jun 2025·Signal Transduction and Targeted Therapy

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.

Article

Author: Wang, Feng ; Han, Guohong ; Wang, Yaolin ; Millward, Michael ; Lee, Myung-Ah ; Nordman, Ina ; Ruan, Dan-Yun ; Yan, Dong ; Richardson, Gary ; Xu, Ye ; Zhang, Yihong ; Zhang, Ling ; Grewal, Jaspreet ; Huh, Seok Jae ; Lee, Keun-Wook ; Xie, Xiaoxi ; Underhill, Craig ; Wu, Hao-Xiang ; Li, Xingya ; Hager, Steven ; Shan, Jianzhen ; Shi, Zhe ; Zhang, Jingdong ; Hu, Xiaohua ; Sanborn, Rachel E ; Wei, Shaozhong ; Xu, Rui-Hua ; Xiang, Ziyong ; Deng, Yanhong ; Hou, Xinfang ; Luo, Laisheng ; Gadgeel, Shirish M ; Pan, Hongming ; Munster, Pamela N

Mutations in the KRAS gene have long been implicated in the pathogenesis of colorectal cancer (CRC). KRAS G12C inhibitors overcome the "undruggable" challenge, enabling precision therapy. Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor, has demonstrated promising anti-tumor activity and favorable safety profile in early clinical trials. We conducted an open-label, nonrandomized phase II trial (ClinicalTrials.gov, NCT04585035) to assess the safety and efficacy of garsorasib with or without cetuximab in KRAS G12C-mutated CRC. In the monotherapy cohort (n = 26), objective response rate (ORR) was 19.2% (95% CI, 6.6-39.4), disease control rate (DCR) was 92.3% (95% CI, 74.9-99.1), median progression-free survival (PFS) was 5.5 months (95% CI, 2.9-11.6) and median overall survival (OS) was 13.1 months (95% CI, 9.5-NE). In the combination cohort (n = 42), ORR was 45.2% (95% CI, 29.8-61.3), DCR was 92.9% (95% CI, 80.5-98.5), median PFS was 7.5 months (95% CI, 5.5-8.1), and median OS was not reached. Grade ≥3 treatment-related adverse events occurred in 5 (19.2%) and 6 (14.3%) patients in monotherapy and combination cohort, respectively. Garsorasib with or without cetuximab showed a promising efficacy and manageable safety profiles in heavily pretreated patients with KRAS G12C-mutated CRC, providing a potential new treatment approach for such population.

News (Medical) associated with Garsorasib

01 Jun 2025

·www.prnewswire.com

InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025

NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of ifebemtinib (IN10018), an oral focal adhesion kinase (FAK) inhibitor in combination with garsorasib (D-1533), an oral KRAS G12C inhibitor, in KRAS G12C mutant solid tumors. The clinical data presented at the 2025 ASCO Annual Meeting (Abstract #8629 | Poster Board #109) included results from two cohorts: Durability follow-up data of the single-arm cohort in first-line KRAS G12C-mutant non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 expression, who received ifebemtinib + garsorasib treatment. A randomized cohort in previously treated KRAS G12C-mutant colorectal cancer (CRC) patients comparing ifebemtinib+ garsorasib versus garsorasib monotherapy. In NSCLC cohort, the combination of ifebemtinib and garsorasib, as a dual-oral, chemotherapy-free regimen, demonstrated compelling clinical benefit including high response rates and durable efficacy, regardless of PD-L1 expression, and in CRC cohort, the result showed clear add-on efficacy by ifebemtinib compared to KRAS inhibitor monotherapy. Key Highlights in First-line NSCLC: Dual-Oral Regimen Shows Durable Efficacy and Emerging Survival Benefit As of March 31, 2025, 33 first-line NSCLC patients, regardless of PD-L1 expression, were enrolled and received the combination of ifebemtinib and garsorasib, with a median follow-up of 16.0 months. Previously the company has reported an Objective Response rate (ORR) of 90.3% (data presented at ESMO 2024). The follow-up data were now summarized as follows: Median progression-free survival (mPFS): 22.3 months Median duration of response DOR (mDOR): 19.4 months Median overall survival (mOS): not yet reached, with a significant uplifting and flattening survival curve indicating durable benefit. Of note, the treatment demonstrated consistent efficacy regardless of PD-L1 expression status. Key Findings in Previously Treated CRC: Randomized Trial Validates Synergy with KRAS G12Ci As of Apr 21, 2025, 36 previously treated CRC patients were randomized 1:1 to receive the combination of ifebemtinib + garsorasib or garsorasib alone. All patients were radiologically evaluable and the antitumor responses were assessed and summarized as follows: ORR: 44.4% (combo) vs. 16.7% (mono) D isease control rate (DCR): 100.0% (combo) vs. 77.8% (mono) mPFS: 7.7 months (combo) vs. 4.0 months (mono) mOS: not yet reached in the combination arm; early separation observed in the survival curves "These results validate ifebemtinib as an ideal combination partner for RAS inhibitors in RAS-driven malignancies to boost efficacy of RASi significantly," said Dr. Zaiqi Wang, Chief Executive Officer of InxMed. "The unprecedented 19-month DOR and 22-month median PFS in front-line NSCLC in all comers and near doubling of response rate in CRC position this dual-oral regimen as a potential paradigm shift treatment in KRAS G12C-mutant cancers. Its favorable safety profile further supports the potential for a cytotoxic chemotherapy-free regimen in winning front-line in the future." InxMed has initiated a randomized Phase III pivotal trial in first-line KRAS G12C-mutant NSCLC. Additionally, the company is actively exploring combinations of ifebemtinib with other KRAS-targeted agents, including KRAS G12D inhibitors and multi-RAS inhibitors, supported by promising preclinical synergy data. About Ifebemtinib (IN10018) Ifebemtinib (IN10018) is a highly selective, orally administered, small molecule inhibitor against FAK, which has significant synergies with a broad spectrum of therapeutic modalities. Clinically, it has demonstrated therapeutic synergies with chemotherapy, targeted therapies, and immunotherapies. To date, over 600 patients have been treated with a favorable safety and tolerability profile. Ifebemtinib has been granted Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA) and Fast-Track D esignation from the U.S. Food and Drug Administration (FDA). A New Drug Application submission to the NMPA is planned for 2025. About InxMed Founded in 2018, InxMed is a clinical-stage biotech company dedicated to developing innovative therapies against resistance and metastasis in cancer. The company integrates deep insights in tumor biology with translational research capabilities to develop novel therapies targeting tumor defense mechanism. InxMed has built an efficient engine for clinical translational research driven by an in-depth understanding of disease biology. InxMed is conducting a registrational trial in platinum-resistant ovarian cancer and first-line NSCLC with KRAS G12C mutation in China, alongside multiple proof-of-concept studies in lung, colorectal, melanoma, and pancreatic cancers, with selected tumor types progressing toward pivotal trials. InxMed's pipeline includes several compounds targeting tumor defense mechanisms with highly differentiated therapeutic candidates. For more information, please visit en.inxmed.com. SOURCE InxMed (Nanjing) Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Fast TrackImmunotherapyBreakthrough Therapy

21 Nov 2024

·www.prnewswire.com

InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration (NMPA) has granted Ifebemtinib (IN10018) Breakthrough Therapy designation (BTD) for the first-line (1L) treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation in combination with garsorasib, a specific inhibitor of the KRAS G12C mutation. This is the second BTD ifebemtinib received. In April 2022, ifebemtinib was granted its first BTD for the treatment of platinum-resistant ovarian cancer (PROC) in combination with PEG-liposomal doxorubicin (PLD). Ifebemtinib is a highly selective, orally administered, small molecule inhibitor for focal adhesion kinase, which has demonstrated significant clinical synergies with targeted therapies, immunotherapies, and standard chemotherapies. The BTD is supported by the data from the Phase Ib/II study evaluating the efficacy and safety of ifebemtinib in combination with garsorasib for the 1L treatment of NSCLC with KRAS G12C mutation (NCT06166836). The results of the clinical trial were featured at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The dual-oral regimen showed promising antitumor efficacy with a well-tolerated safety profile in 1L KRASG12C NSCLC. The objective response rate (ORR) was 90.3% and the disease control rate (DCR) was 96.8%. A total of 28 confirmed partial responses (PRs) and two stable diseases (SDs) were reported from 31 efficacy evaluable patients. All treated patients have achieved a follow-up visit of 9 months so far, and the median PFS has not been reached at the time of this report. Beyond KRAS G12C inhibitors, Ifebemtinib has also shown significant therapeutic synergies when combined with a wide range of standard and emerging cancer treatments, such as anti-PD-(L)1 antibodies, other RAS-targeted inhibitors, EGFR inhibitors, and ADCs. InxMed is actively pursuing collaborations with innovating partners globally。 InxMed is currently conducting a registrational trial in platinum-resistant ovarian cancer in China, for which the company plans to submit a New Drug Application to the NMPA in 2025. InxMed also has multiple proof-of-concept trials ongoing in lung, colorectal, melanoma, and pancreatic cancers, some of which will progress into pivotal studies. Thus far, more than 600 subjects have been treated with ifebemtinib, and a favorable safety and tolerability profile has been observed. About InxMed InxMed Co. Ltd is a clinical-stage biotech company developing innovative therapies against tumor treatment resistance and metastasis. Established in 2018, InxMed has built an efficient engine for clinical translational research driven by an in-depth understanding of disease biology. InxMed's pipeline includes several compounds targeting tumor defense mechanisms with highly differentiated therapeutic candidates. For more information, please visit en.inxmed.com. SOURCE InxMed (Shanghai) Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultASCOBreakthrough TherapyImmunotherapyClinical Study

09 Jul 2024

·www.biospace.com

Global KRAS Inhibitors Drug Sales Is Expected To Surpass USD 600 Million By 2030

At Present Only 2 Drugs Are Approved In Market With More Than 90 Drugs In Clinical Trials KRAS-targeted therapies have emerges as a groundbreaking opportunity in oncology drug development, addressing a long-standing challenge in cancer treatment. after decades of being considered “undruggable”, the KRAS protein has finally succumbed to therapeutic intervention, opening a substantial commercial opportunity for pharmaceutical companies. The market for these therapies has shown a remarkable growth since the first approval in 2021, exceeding US$ 300 million in 2023, driven by high unmet medical needs and the prevalence of KRAS mutations in various cancers. Download KRAS Inhibitors Commercial & Clinical Development Insight As of July 2024, two KRAS targeted therapies have received approval. The first, Lumakras (sotorasib) from Amgen, was approved in May 2021 for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. The second, Krazati (adagrasib) from Mirati Therapeutics, received approval in December 2022, also for NSCLC patients with KRAS G12C mutations. Furthermore, in June 2024, it received an accelerated approval for the treatment of adult patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) in combination with Erbitux (cetuximab). These approvals have validated the KRAS-targeting approach and paved the way for further development in this space. Currently undergoing late-stage clinical trials and possibly the next in line for regulatory clearance are D-1553 (Garsorasib) from Chia Tai Tianqing Pharmaceutical, Glecirasib (JAB-21822) from Jacobio Pharma, and MK-1084 from Merck, among others. This shows the robust involvement of pharmaceutical companies around the world working to improve treatment outcomes for patients with KRAS-mutated cancers. In addition, certain regional drug regulatory agencies have accepted the New Drug Application (NDA) for Glecirasib and Garsorasib, as well as a few others. These drugs are anticipated to be approved and launched within the next year. The commercial opportunity for KRAS-targeted therapies is significant, underpinned by several key factors. KRAS mutations occur in approximately 25% of all cancers, with particularly high frequencies in pancreatic cancer, colorectal cancer and lung cancer. This translates into a substantial patient population, providing a large addressable market. While current approved therapies majorly focus on the G12C mutations, such as G12V and G12D. Success in these areas would significantly expand the market potential. Combination therapies represent another avenue for growth. KRAS inhibitors are being studies in combination with targeted therapies, immunotherapies, and standard-of-care treatments. For instance, Sidney Kimmel Comprehensive Cancer Center is conducting a Phase 1 clinical trial assessing the combination of a KRAS-targeted vaccine with Nivolumab (anti-PD-1) and Ipilimumab (anti-CTLA-4) for patients with NSCLC. Successful combinations could lead to improved efficacy, expanded indications, and increased market share. Additionally, the global potential is considerable. Initial approvals have focused on the US market, but global expansion presents significant opportunities, particularly in Europe and Asia. As precision medicines addressing a critical unmet need, KRAS-targeted therapies command premium pricing. For example, Lumakras is priced at approximately US$ 22,245 per month in the US. This pricing strategy, combined with the potential for label expansion to other KRAS-mutated cancers, further enhances the commercial prospects of these therapies. The rapid market growth and intense research activity in this field suggests that KRAS-targeted therapies will continue to be a major focus of for pharmaceutical companies and investors. As more data emerges from ongoing clinical trials and potentially new approvals are granted, the market is expected to expand significantly in the coming years, possibly reaching billions of dollars annually within the next decade.

Drug ApprovalPhase 1VaccineAccelerated Approval

100 Deals associated with Garsorasib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
KRAS G12C mutant Non-small Cell Lung Cancer	China	Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.	05 Nov 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-squamous non-small cell lung cancer	Phase 3	-	Inxmed (Shanghai) Co., Ltd	01 Sep 2025
KRAS Mutant Pancreatic Cancer	Phase 2	China	InventisBio, Co., Ltd.	24 Apr 2025
Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	InventisBio, Co., Ltd.	22 Dec 2021
KRAS G12C mutation Solid Tumors	Phase 2	China	InventisBio, Co., Ltd.	22 Dec 2021
Colorectal Cancer	Phase 2	United States	InventisBio, Co., Ltd.	02 Oct 2020
Colorectal Cancer	Phase 2	Australia	InventisBio, Co., Ltd.	02 Oct 2020
Colorectal Cancer	Phase 2	Taiwan Province	InventisBio, Co., Ltd.	02 Oct 2020
Locally Advanced Malignant Solid Neoplasm	Phase 2	United States	InventisBio, Co., Ltd.	02 Oct 2020
Locally Advanced Malignant Solid Neoplasm	Phase 2	Australia	InventisBio, Co., Ltd.	02 Oct 2020
Locally Advanced Malignant Solid Neoplasm	Phase 2	Taiwan Province	InventisBio, Co., Ltd.	02 Oct 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04585035 (phase II trial in advanced solid tumors with KRAS G12C mutation, Pubmed \| Signal Transduct Target Ther)	Phase 2	KRAS G12C mutation Solid Tumors KRAS G12C mutation	-	Garsorasib monotherapy	ihgtdhpwwf(pgkapureug) = mdpxwmbbch afzybjehor (opauszxzvu, 74.9 - 99.1) View more	Positive	17 Jun 2025
	Phase 2	KRAS G12C mutation Solid Tumors KRAS G12C mutation	-	Garsorasib + Cetuximab combination therapy	ihgtdhpwwf(pgkapureug) = lqqxfhnpwq afzybjehor (opauszxzvu, 80.5 - 98.5) View more	Positive	17 Jun 2025
NCT06166836 \| NCT05379946 (ESMO2024) Manual	Phase 1/2	KRAS G12C mutation Solid Tumors Second line \| First line KRAS G12C	48	Ifebemtinib (100mg qd) + D-1553 (600mg bid)	ityveithet(ogjppsaoap) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. ncoxzbecfm (peapgjfgii ) View more	Positive	14 Sep 2024
NCT06166836 \| NCT05379946 (ESMO2024) Manual	Phase 1/2		48	Ifebemtinib (100mg qd) + D-1553D-1553 (600mg bid) (KRAS G12C mutant metastatic CRC)		Positive	14 Sep 2024
NCT05383898 (WCLC2024) Manual	Phase 2	KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C	123	Garsorasib 600 mg	bzyibnvegp(toyrtvvnkq) = jdklxnayzd iifqhuidez (akdwgbbcto, 42.8 - 61.1) View more	Positive	09 Sep 2024
NCT05383898 (Pubmed) Manual	Phase 2	KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C	123	Garsorasib 600 mg	yqyanzawbr(dpavriaawh) = feygledbzs uxmhiasyxa (doibsnlzif, 41 - 59) View more	Positive	10 Jun 2024
AACR2024 Manual	Phase 2	KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C	123	Garsorasib 600 mg	agpxolqceh(jlwboqhlxw) = keiyvedooy ofnwovlvpj (ugstepogdc, 40.5 - 58.8) View more	Positive	05 Apr 2024
NCT04585035 \| NCT05383898 (ESMO 12023 \| ESMO 22023) Manual	Phase 1/2	KRAS p.G12C mutant pancreatic cancer KRAS G12C Mutation	10	D-1553	vwggrasjba(goacsuqhhr) = hhnqporxpm zztjujkxbo (ezzszcwptg, 1.25 - NA) View more	Positive	23 Oct 2023
NCT04585035 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	KRAS G12C mutant Colorectal Cancer KRAS G12C	29	D-1553+cetuximab	bhqadyeeoc(jmpskjnwez) = ytllijajme xibgznyuks (rqbgmisapf ) View more	Positive	21 Oct 2023
NCT05383898 (D-1553, Pubmed \| J Thorac Oncol)	Phase 1	Non-Small Cell Lung Cancer KRAS G12C-mutated	79	D-1553 600 mg once daily	hpprddlcne(uouqwprlzn) = kfrzsxeddd fiuqdjuzix (pkogrgrbej ) View more	Positive	01 Jul 2023
NCT05383898 (D-1553, Pubmed \| J Thorac Oncol)	Phase 1	Non-Small Cell Lung Cancer KRAS G12C-mutated	79	D-1553 800 mg once daily	hpprddlcne(uouqwprlzn) = rlayfbykzf fiuqdjuzix (pkogrgrbej ) View more	Positive	01 Jul 2023
NCT04585035 (ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	KRAS G12C mutant Colorectal Cancer KRAS G12C Mutation	24	D-1553	wxryarekpb(tiheydhmed) = dhlnbjbfhc rbohosxsbo (ukumpozfcg, 2.89 - 9.53) View more	Positive	31 May 2023
NCT05383898 (WCLC2022)	Phase 1	Metastatic Solid Tumor \| Non-Small Cell Lung Cancer	79	D-1553 600 mg QD	omgmsgznsv(aowlzdjhon) = vswwkljorb pxrvenlgpa (kjsqdhlexa ) View more	-	06 Aug 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Garsorasib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation